InvestorsHub Logo
icon url

SF Anony

02/13/21 12:16 AM

#146730 RE: CTMedic #146727

Compelling information, CT. I eagerly await kgromax's reply, as it every bit of information we investors get as study results near can be helpful in our decision-making. Decisions such as "Should I start looking at prices for airline tickets to Vegas?"
icon url

CI Ventures

02/13/21 12:56 AM

#146732 RE: CTMedic #146727

Respect!! First round in Vegas is on me to all longs!!
icon url

C-20

02/13/21 1:20 AM

#146736 RE: CTMedic #146727

CTMedic- great post. I’m not sure any response is needed . What else would you say
icon url

golfer999

02/13/21 7:44 AM

#146746 RE: CTMedic #146727

According to this link, mechanical ventilation was an exclusion criteria for this trial. Look at exclusion criteria number 5. https://www.clinicaltrials.gov/ct2/show/NCT04356937
icon url

BBalls-N-CowTown

02/13/21 11:41 AM

#146760 RE: CTMedic #146727

This supports the prediction put forward by the mysterious Dr. Tap. Shorts will be burned mercilessly, and go to skid row where Nader will forever live in their minds rent-free. Nader Detangement Syndrome will reach epidemic proportions as the stock gaps up in lock-limit and shoots past $100, never to return. All of this in a fantastic stock available for the price of only 3 mega million lottery tickets!
icon url

tradero

02/13/21 3:52 PM

#146786 RE: CTMedic #146727

Thank you CTMedic! Great post

There it goes my only allowed post for the day
icon url

kgromax

02/17/21 8:36 AM

#147339 RE: CTMedic #146727

Yep I am pretty sure. The paper I posted clearly shows a big mortality jump when CRP goes from 50 to 100.
Several papers have also shown CRP is the BEST SINGLE VARIABLE to assess the severity of COVID for a patient. Better than age, comorbidities or any other predictor.
Filtering on CRP>75 as the Toci study did rejected low-risk patients as the statistics demonstrate.
That, plus the fact that Cytodyn rejected high-risk patients (inclusion criteria n°3 in Cytodyn's study) explains why Cytodyn's study is selecting on average much lower risk patients than the Toci's study. So mortality will be below Toci's study, by a 3% + 3% = 6% gap as I estimated in my posts based on available research papers. Said otherwise, Cytodyn's trial shall failed as this will bring back Cytodyn's placebo arm mortality too close to thee Leronlimab arm mortality for any statistical significance to be reached.